EUVIMEDEUVIMED entdecken
Crossref

Pharmacodynamic Interaction Between Emicizumab and Coagulation Factor VIII

Matthias Chill, Emma L Konarski, Annika Klingberg, Birgitt Haarmeijer, Sonja Werwitzke, Andreas Tiede iD, Olga Oleshko iD

Thrombosis and Haemostasis · 12.02.2026

DOI: 10.1055/a-2800-4026 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thrombosis and Haemostasis, erschienen am 12.02.2026. Verfasst von Matthias Chill und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany. Die Arbeit nennt 24 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Emicizumab is a bispecific monoclonal antibody that mimics the cofactor function of activated factor (F) VIIIa, facilitating the FIXa-catalyzed activation of FX. Emicizumab binds to FIX/IXa and FX with considerably lower affinity than FVIIIa, suggesting that FVIII may outcompete emicizumab when present at higher concentrations. However, the interaction between emicizumab and FVIII at low FVIII concentrations is not well characterized. The current study aimed to assess the pharmacodynamic interaction between emicizumab and FVIII using classical pharmacological concepts of additivity and synergy. Thrombin generation was used as a surrogate marker of hemostatic capacity, providing well-defined quantitative outcome parameters. Tissue factor-triggered thrombin generation was measured in FVIII-deficient plasma supplemented with variable concentrations of emicizumab and recombinant FVIII, alone or in combination. A synergistic interaction between emicizumab and FVIII was observed, resulting in enhanced endogenous thrombin potential and peak thrombin generation beyond the levels expected from either agent alone. This synergistic effect was evident at low FVIII concentrations and was no longer observed once FVIII levels exceeded 20 IU/dl. These findings may provide a pharmacodynamic explanation for the pronounced hemostatic effect of emicizumab at low FVIII levels and offer a conceptual framework for evaluating synergistic interactions between novel non-factor therapies and intrinsic FVIII.

Autor:innen und Institutionen

  • Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
  • Institute of Clinical Chemistry and Central Laboratory, Hannover Medical School, Hannover, Germany.

ORCID-Profile: Andreas Tiede, Olga Oleshko

Zitieren

APA

Chill, M., Konarski, E. L., Klingberg, A., Haarmeijer, B., Werwitzke, S., Tiede, A., & Oleshko, O. (2026). Pharmacodynamic Interaction Between Emicizumab and Coagulation Factor VIII. Thrombosis and Haemostasis. https://doi.org/10.1055/a-2800-4026

Vancouver

Chill M, Konarski EL, Klingberg A, Haarmeijer B, Werwitzke S, Tiede A, et al. Pharmacodynamic Interaction Between Emicizumab and Coagulation Factor VIII. Thrombosis and Haemostasis. 2026. doi:10.1055/a-2800-4026

BibTeX
@article{Chill2026,
  author = {Chill, Matthias and Konarski, Emma L and Klingberg, Annika and Haarmeijer, Birgitt and Werwitzke, Sonja and Tiede, Andreas and Oleshko, Olga},
  title = {Pharmacodynamic Interaction Between Emicizumab and Coagulation Factor VIII},
  journal = {Thrombosis and Haemostasis},
  year = {2026},
  doi = {10.1055/a-2800-4026}
}
Kostenlos starten →